Papanicolas Irene, Niksch Maecey, Figueroa Jose F
Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, Rhode Island.
Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
JAMA Intern Med. 2025 May 1;185(5):583-590. doi: 10.1001/jamainternmed.2025.0155.
Although there are increasing differences in health policy and population health across US states over the past decade, little is known about how US states compare with other countries on avoidable mortality.
To compare trends in avoidable mortality across US states and countries in the European Union (EU) and the Organisation for Economic Co-operation and Development (OECD).
DESIGN, SETTING, AND PARTICIPANTS: Retrospective, population-based, repeated cross-sectional study comparing changes in avoidable mortality among decedents aged 0 to 74 years in 50 US states (and Washington, DC) and 40 high-income countries between 2009 and 2021. Data analysis was conducted from May to July 2024.
Avoidable mortality comprising both preventable deaths related to prevention and public health and treatable deaths related to timely and effective health care treatment.
Between 2009 and 2019, total avoidable mortality increased in all US states (median [IQR], 29.0 [20.1 to 44.2] deaths per 100 000 people), while it decreased in most comparator countries (-14.4 [-28.4 to -8.0]). During this period, variation in avoidable mortality widened across US states (2009: median [IQR], 251.1 [228.4 to 280.4]; 2019: 282.8 [249.1 to 329.5]), but narrowed in comparator countries (2009: 201.5 [166.2 to 320.8]; 2019: 187.1 [152.0 to 298.2]). During the COVID-19 pandemic (2019-2021), avoidable mortality increased for all US states (median [IQR], 101.5 [64.7 to 143.1]) and comparator countries (25.8 [9.1 to 117.7]). The states and countries that experienced the greatest increase in avoidable deaths during the COVID-19 period were those with the highest baseline avoidable mortality (Pearson ρ = 0.86; P < .001). Health spending and avoidable mortality have a consistent, negative, and significant association among comparator countries (2019: Pearson ρ = -0.7; P < .001) but no statistically significant association within US states (2019: Pearson ρ = -0.12; P = .41).
This cross-sectional study found that the stark contrast in avoidable mortality trends between all US states compared with EU and OECD countries suggests that broad, systemic factors play a role in worsening US population health. While other countries appear to make gains in health with increases in health care spending, such an association does not exist across US states, raising questions regarding US health spending efficiency.
尽管在过去十年中,美国各州在卫生政策和人口健康方面的差异日益增大,但对于美国各州在可避免死亡率方面与其他国家相比情况如何,人们了解甚少。
比较美国各州与欧盟(EU)及经济合作与发展组织(OECD)国家在可避免死亡率方面的趋势。
设计、背景和参与者:一项回顾性、基于人群的重复横断面研究,比较了2009年至2021年期间美国50个州(及华盛顿特区)和40个高收入国家中0至74岁死者的可避免死亡率变化。数据分析于2024年5月至7月进行。
可避免死亡率,包括与预防和公共卫生相关的可预防死亡以及与及时有效的医疗保健治疗相关的可治疗死亡。
2009年至2019年期间,美国所有州的总可避免死亡率均有所上升(中位数[四分位间距],每10万人中有29.0[20.1至44.2]人死亡),而大多数可比国家的这一指标则有所下降(-14.4[-28.4至-8.0])。在此期间,美国各州之间可避免死亡率的差异有所扩大(2009年:中位数[四分位间距],251.1[228.4至280.4];2019年:282.8[249.1至329.5]),但可比国家的差异则有所缩小(2009年:201.5[166.2至320.8];2019年:187.1[152.0至298.2])。在2019-2021年的新冠疫情期间,美国所有州(中位数[四分位间距],101.5[64.7至143.1])和可比国家(25.8[9.1至117.7])的可避免死亡率均有所上升。在新冠疫情期间可避免死亡人数增加最多的州和国家,是那些基线可避免死亡率最高的州和国家(皮尔逊相关系数ρ = 0.86;P <.001)。在可比国家中,卫生支出与可避免死亡率之间存在一致、负向且显著的关联(2019年:皮尔逊相关系数ρ = -0.7;P <.001),但在美国各州内部则无统计学上的显著关联(2019年:皮尔逊相关系数ρ = -0.12;P = 0.41)。
这项横断面研究发现,美国所有州与欧盟及经合组织国家在可避免死亡率趋势上的鲜明对比表明,广泛的系统性因素在使美国人口健康状况恶化方面发挥了作用。虽然其他国家似乎随着医疗保健支出的增加在健康方面取得了进展,但在美国各州之间不存在这种关联,这引发了对美国卫生支出效率的质疑。